{
event: "article_read",
name: `Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?`,
author: ``,
tags: `Nasal Polyps`,
publication_date: ``,
interaction_type: "content"
}
Read article
Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
Over 80% of CRS with Nasal Polyps’ Patients have Type 2 Inflammation Dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.
.png/jcr:content/image%20(24).png)
Related articles
.png0/jcr:content/jcr_content%20(1).png)
Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?
MAT-KW-2400275/V1/MAY2024